OncLive® On Air

S19 Ep3: FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia

S19 Ep2: FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

S19 Ep2: Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

S18 Ep50: Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape

S18 Ep49: Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings

S18 Ep48: OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma

S18 Ep47: Dissecting Diagnostic and Management Factors in Systemic Mastocytosis

S18 Ep46: Unpacking Data and Upcoming Developments for Olverembatinib in CML

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

Individualizing treatment for hormone receptor-positive, HER2-negative metastatic breast cancer requires integrating molecular profiling with clinical assessment of disease progression. Genomic testing for PIK3CA and ESR1 mutations informs the selection of targeted therapies, including PI3K/AKT/mTOR inhibitors and next...

S18 Ep44: Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

The treatment of colorectal cancer is undergoing a paradigm shift as neoadjuvant immunotherapy moves to the forefront of clinical practice. Dr. Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, highlights how mismatch repair deficient (MSI-high) tumors exhibit exceptional sensitivity to checkpoint...

S18 Ep42: Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

S18 Ep41: Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

S18 Ep39: Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond

Pancreatic cancer treatment is shifting toward more targeted, mutation-specific strategies and refined chemotherapy regimens. The NAPOLI-3 trial demonstrates that the NaliriFox regimen—liposomal irinotecan, oxaliplatin, and 5-FU—significantly improves overall survival compared to gemcitabine and nab-paclitaxel, while o...

S18 Ep34: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care

Advanced gastroesophageal adenocarcinoma management requires mandatory testing for HER2, Claudin 18.2, mismatch repair deficiency, and PD-L1 to guide targeted therapy. Clinical evidence establishes the triplet regimen of zanidatamab, tislelizumab, and chemotherapy as a new standard of care, though clinicians must proac...

S18 Ep38: Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

S18 Ep36: Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD